Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
NaviFUS Corporation
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06496971CT.gov A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients | — | Recruiting | — | — | — |
NCT04525014CT.gov RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors | — | Terminated | — | — | — |
NCT04239092CT.gov 9-ING-41 in Pediatric Patients With Refractory Malignancies. | — | Terminated | — | — | — |
NCT04074785CT.gov Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | — | Terminated | — | — | — |
NCT03426891CT.gov Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
NCT01967810CT.gov ANG1005 in Patients With Recurrent High-Grade Glioma | — | Completed | — | — | — |
NCT01814813CT.gov Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT01582152CT.gov Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | — | Terminated | — | — | — |
NCT01609790CT.gov Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | — | Completed | — | — | — |
NCT01518413CT.gov Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT01342757CT.gov Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | — | Completed | — | — | — |
NCT01189240CT.gov RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | — | Terminated | — | — | — |
NCT00641706CT.gov Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00597402CT.gov Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | — | Completed | — | — | — |
NCT00238303CT.gov Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT02055196CT.gov Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | NaviFUS Corporation | P3 | BB · 66 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Temsirolimus | M.D. Anderson Cancer Center | P2 | BBB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Dexmedetomidine | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vorinostat | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Nivolumab | InSightec | P3 | BB |
| Nogitecan | Jeffrey N. Bruce | P2 | BB |
| Cyclophosphamide | Essen Biotech | P3 | BB |
+41 more in the Brain Neoplasm cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Brain Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-brain-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →